Streetbeat News

Regulatory

SAVA

Cassava Sciences Inc (NASDAQ:SAVA) is advancing its Alzheimer's drug, simufilam, through Phase 3 trials. The trials are crucial for determining the drug's efficacy and safety, with results expected by December 2024 and June 2025. The company faces ongoing investigations by the DOJ and SEC, and the credibility of its clinical trial results has been questioned by the FDA.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 6:03 pm

LLY

NVO

PFE

RHHBY

The development of oral weight loss medications is gaining momentum with companies like Eli Lilly, Novo Nordisk, Pfizer, and Roche leading the charge. While oral drugs offer advantages over injectables, such as reduced costs and no need for refrigeration, they face challenges like production issues and potential side effects. Novo Nordisk's Rybelsus is currently the only authorized oral GLP-1 drug, but other companies are making significant progress in clinical trials.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 5:42 pm

TLRY

Tilray Brands, Inc. (NASDAQ:TLRY) announced that its German facility, Aphria RX GmbH, has obtained a new cannabis cultivation license under Germany's new Cannabis Act. This license will allow Tilray to quintuple its medical marijuana production in Germany, expanding from three to 31 approved strains. The new law also partially legalizes recreational cannabis in Germany.

Portfolio Pulse from Jelena Martinovic

July 22, 2024 | 5:05 pm

BIIB

IONS

RARE

Ionis Pharmaceuticals (NASDAQ: IONS) released positive results from its Phase 1/2 study of ION582 for Angelman syndrome, showing significant clinical improvements and favorable safety. William Blair reiterated an Outperform rating, noting the drug's potential benefits and differentiation from Ultragenyx's (NASDAQ: RARE) program. Ionis plans to meet with regulators for Phase 3 study design and expects pivotal study initiation in early 2025. The next 12-18 months could be transformative for Ionis with multiple product launches and potential approvals.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 5:04 pm

CYTH

Cyclo Therapeutics has been granted European Patent Number EP3873604 for methods of treating Alzheimer's disease with HP-[beta]-cyclodextrin. This patent could enhance the company's intellectual property portfolio and potentially boost its market position in Alzheimer's treatment.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 5:02 pm

AMZN

GOOG

GOOGL

META

Vice President Kamala Harris, endorsed by President Biden as the 2024 Democratic nominee, is advocating for AI regulation and the regulation of big technology companies. Harris has a history with the tech sector and has called for AI regulation to protect public safety and privacy. She has not pushed for breaking up big tech companies like Amazon, Alphabet, and Meta, but has emphasized the need for regulation to ensure consumer privacy. The potential ban of TikTok is also a topic, with Harris opposing a ban but expressing national security concerns.

Portfolio Pulse from Chris Katje

July 22, 2024 | 4:57 pm

SPY

The Federal Communications Commission (FCC) reported that an AT&T Wireless outage in February blocked over 92 million U.S. calls and prevented more than 25,000 attempts to reach 911.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 4:46 pm

ALLR

Allarity Therapeutics Inc (NASDAQ:ALLR) received a Wells Notice from the SEC regarding disclosures about their NDA for Dovitinib. The notice suggests potential legal action but is not a formal charge. The company plans to respond formally and has proposed a reverse stock split to regain NASDAQ compliance. Allarity will focus on advancing stenoparib and has a financial runway extending into 2026.

Portfolio Pulse from Vandana Singh

July 22, 2024 | 4:30 pm

MSFT

Microsoft has responded to the FTC's criticism regarding changes to Xbox Game Pass, including price hikes and the discontinuation of the console-only tier. Microsoft argues that the FTC's claims are misleading and that the new Standard tier offers more value than the previous console-only option.

Portfolio Pulse from Franca Quarneti

July 22, 2024 | 4:12 pm

GOOG

GOOGL

Google announced that starting August 7th, 2024, it will update its Google Ads Gambling & Games Policy for Peru. The update will allow ads from operators licensed by the Ministry of Foreign Trade & Tourism.

Portfolio Pulse from Benzinga Newsdesk

July 22, 2024 | 4:00 pm